New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2014
08:02 EDTCVMCEL-SCI receives $225K NIH research grant
CEL-SCI announced that it has been awarded a Phase I Small Business Innovation Research grant in the amount of $225K from the National Institute of Arthritis Muscoskeletal and Skin Diseases, which is part of the National Institutes of Health. The grant will fund the further development of CEL-SCI’s LEAPS technology as a potential treatment for rheumatoid arthritis. The NIH grant was awarded based on preliminary data by Tibor Glant’s team in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI's LEAPS technology prevented the development, and lessened the severity, including inflammation, of experimental RA when it was administered after the disease was induced in the animals. This data was presented in May 2013 by Daniel Zimmerman, CEL-SCI’s senior vice president of research, cellular immunology, at the symposium on “Therapeutic Approaches to Autoimmunity” during the American Association of Immunologists 100th annual meeting in Honolulu, Hawaii.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2016
10:00 EDTCVMCEL-SCI says enrolled 29 patients in Phase 3 Multikine trial in January
CEL-SCI Corporation announced that during the month of January it has enrolled 29 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine in patients with advanced primary head and neck cancer. Total patient enrollment for the trial is now 697 as of January 31, 2016 in the Phase 3 study in head and neck cancer. The current study goal is to enroll 880 patients through approximately 100 clinical centers in over 20 countries. The Multikine Phase 3 study is enrolling patients with advanced primary squamous cell carcinoma of the head and neck. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus standard of care vs. subjects who are treated with SOC only.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use